Enter your email address
Submit
Write your message
Volume 15, Issue 4 (Iranian Journal of Breast Diseases 2023)
ijbd 2023, 15(4): 33-50 |
Back to browse issues page
Ethics code: 198109
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahador M, Gilani S, Moazed V, Mokhtari Ardekani A, Larizadeh M H. Association of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio with Pathologic Response to Neoadjuvant Chemotherapy in Nonmetastatic Advanced Breast Cancer Subtypes in Kerman. ijbd 2023; 15 (4) :33-50
URL: http://ijbd.ir/article-1-974-en.html
URL: http://ijbd.ir/article-1-974-en.html
Maryam Bahador1 
, Shahrzad Gilani 2, Vahid Moazed3 , Abnoos Mokhtari Ardekani4 , Mohammad hasan Larizadeh5
, Shahrzad Gilani 2, Vahid Moazed3 , Abnoos Mokhtari Ardekani4 , Mohammad hasan Larizadeh5
1- Department of Radiotherapy, Kerman University of Medical Sciences, Kerman, Iran
2- Radiation Oncology Resident, Department of Radiation Oncology, Afzalipour hospital, Kerman University of Medical Sciences, Kerman, Iran , mrs.shahrzad66@gmail.com
3- Department of Oncology, Kerman University of Medical Sciences, Kerman, Iran
4- Endocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran
5- Department of Radiation Oncology, Kerman University of Medical Sciences, Kerman, Iran
2- Radiation Oncology Resident, Department of Radiation Oncology, Afzalipour hospital, Kerman University of Medical Sciences, Kerman, Iran , mrs.shahrzad66@gmail.com
3- Department of Oncology, Kerman University of Medical Sciences, Kerman, Iran
4- Endocrinology and Metabolism Research Center, Kerman University of Medical Sciences, Kerman, Iran
5- Department of Radiation Oncology, Kerman University of Medical Sciences, Kerman, Iran
Abstract: (1562 Views)
Introduction: Researchers have increasingly focused their concentration on the prognostic part played by inflammatory indices, such as the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR). In breast cancer, the therapeutic effect of neoadjuvant chemotherapy (differs in patients, and a higher response rate reflects a better outcome. Therefore, the purpose of this study was to assess the association of NLR and PLR with response to neoadjuvant chemotherapy in advanced nonmetastatic breast cancer
Methods: This cross-sectional study was performed on 120 patients with nonmetastatic advanced breast cancer who were candidates for neoadjuvant chemotherapy. Data were collected using a checklist and Peripheral blood samples were evaluated for the calculation of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR). After completion of neoadjuvant chemotherapy and surgery, the response was evaluated based on the pathology report. chi-square test and logistic regression were also used for data analysis.
Results: Patients with a PLR below 126.98 (n = 84) were categorized as having low PLR, and those with a PLR greater than 126.98 (n = 36) were categorized as having high PLR. The high-PLR group showed a significantly greater response to neoadjuvant chemotherapy than the low-PLR group (P = 0.01). NLR was not correlated to the response to neoadjuvant chemotherapy (P = 0.24). An inverse relationship was observed between PLR and tumor size after treatment (P = 0.01). No significant relationship was observed between PLR and age, node status, tumor grade, or Ki67 status. Multivariate analysis showed no significant relationship between ER, PR, or HER2 expression levels and NLR or PLR.
Conclusion: PLR is a good prognostic marker for breast cancer, and patients with a higher PLR respond better to neoadjuvant chemotherapy.
Methods: This cross-sectional study was performed on 120 patients with nonmetastatic advanced breast cancer who were candidates for neoadjuvant chemotherapy. Data were collected using a checklist and Peripheral blood samples were evaluated for the calculation of the neutrophil to lymphocyte ratio (NLR) and the platelet to lymphocyte ratio (PLR). After completion of neoadjuvant chemotherapy and surgery, the response was evaluated based on the pathology report. chi-square test and logistic regression were also used for data analysis.
Results: Patients with a PLR below 126.98 (n = 84) were categorized as having low PLR, and those with a PLR greater than 126.98 (n = 36) were categorized as having high PLR. The high-PLR group showed a significantly greater response to neoadjuvant chemotherapy than the low-PLR group (P = 0.01). NLR was not correlated to the response to neoadjuvant chemotherapy (P = 0.24). An inverse relationship was observed between PLR and tumor size after treatment (P = 0.01). No significant relationship was observed between PLR and age, node status, tumor grade, or Ki67 status. Multivariate analysis showed no significant relationship between ER, PR, or HER2 expression levels and NLR or PLR.
Conclusion: PLR is a good prognostic marker for breast cancer, and patients with a higher PLR respond better to neoadjuvant chemotherapy.
Keywords: Platelet to Lymphocyte Ratio, Neoadjuvant Chemotherapy, Neutrophil to Lymphocyte Ratio, Breast Cancer
Type of Study: Research |
Received: 2022/06/17 | Accepted: 2022/11/21 | Published: 2023/01/21
Received: 2022/06/17 | Accepted: 2022/11/21 | Published: 2023/01/21
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
